Indications for ZERIT:
HIV-1 infection.
Adult Dose for ZERIT:
≥60kg: 40mg every 12hrs; <60kg: 30mg every 12 hrs. Withdraw drug if peripheral neuropathy occurs; after complete resolution, may restart at 20mg every 12 hrs for patients ≥60kg, or 15mg every 12 hrs for patients <60kg; if neuropathy recurs consider discontinuing permanently. Renal impairment: ≥60kg (CrCl 26–50mL/min): 20mg every 12 hrs; (CrCl 10–25mL/min): 20mg every 24 hrs. <60kg (CrCl 26–50mL/min): 15mg every 12 hrs; (CrCl 10–25mL/min): 15mg every 24 hrs. Hemodialysis: ≥60kg: 20mg every 24 hrs; <60kg: 15mg every 24 hrs. Coincide dose for end of dialysis and give at same time of day on non-dialysis days.
Children's Dose for ZERIT:
≤13 days: 0.5mg/kg every 12hrs. ≥14 days: (<30kg): 1mg/kg every 12 hours. ≥30kg: as adult. Withdraw drug if peripheral neuropathy occurs; after complete resolution, may restart at ½ recommended dose; if neuropathy recurs consider discontinuing permanently. Renal impairment: reduce dose or increase dosing interval.
See Also:
ZERIT for ORAL SOLUTION
Pharmacological Class:
Nucleoside analogue (reverse transcriptase inhibitor).
Warnings/Precautions:
Suspend therapy if symptoms of lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occur. Suspend if pancreatitis suspected; may restart if ruled out, monitor closely (do not give with didanosine or hydroxyurea after restarted). Pre-existing liver dysfunction, hepatitis, or other risk factors of liver disease; monitor. Monitor for peripheral neuropathy. Advanced HIV disease, history of peripheral neuropathy, or concomitant neurotoxic drugs: consider reducing dose or discontinuing if neuropathy occurs; may attempt rechallenge at ½ dose. Women, obesity, or prolonged nucleoside exposure: increased risk of toxicity. Renal dysfunction. Diabetes (oral soln). Elderly. Pregnancy (Cat.C): monitor for lactic acidosis if used with didanosine. Nursing mothers: not recommended.
Interactions:
Avoid concomitant zidovudine. Increased risk of toxicity with neurotoxic, hepatotoxic, or pancreatotoxic drugs (eg, didanosine and/or hydroxyurea); avoid. Caution with doxorubicin, ribavirin. Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.
Adverse Reactions:
Headache, GI upset, peripheral neuropathy, rash, elevated liver enzymes, elevated amylase, pancreatitis, lactic acidosis or severe hepatomegaly with steatosis, fat redistribution, immune reconstitution syndrome, anorexia, myalgia.
Note:
Register pregnant patients exposed to stavudine by calling (800) 258-4263.
How Supplied:
Caps—60; Soln—200mL
